Various treatments for psoriasis were used in our study group, with phototherapy being the most common (8.3%), followed by methotrexate (3.1%), anti-TNF agents (1.4%), anti-IL-12/23 agents (0.5%), JAK inhibitors (0.4%), and anti-IL-17 agents (0.3%). The gene discussed is IL17A; the disease is psoriasis.